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license (http://creativesubject of controversy.
Methods: We investigated the correlation between optical coherence tomography (OCT) of the
retinal sublayers, including the retinal nerve fiber layer (RNFL), and cognitive function in subjects
with amnestic MCI and compared the OCT findings with matched controls. We also performed a
meta-analysis of the world literature using a random-effects model.
Results: We found no statistically significant differences in OCT between amnestic MCI (aMCI) and
controls. In aMCI subjects, we found an inverse relationship between RNFL thickness and two cogni-
tive tests (delayed story recall and a word-list learning test and the word-list test). The meta-analysis
revealed a statistically significant decrease in RNFL thickness in MCI subjects.
Discussion: The inverse relationship between cognitive testing and RNFL thickness suggests that
retinal involvement may include paradoxically increased thickness of the RNFL, which could suggest
gliotic reactive changes.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; Mild cognitive impairment; Retinal nerve fiber layer; Optical coherence tomography;Biomarkers1. Introduction
Dementia of Alzheimer’s disease type (DAT) was first
described nearly 110 years ago by the psychiatrist Alois Alz-
heimer [1]. Today, the definitive diagnosis of DAT is made at
brain autopsy, whereas clinical diagnosis and staging in-
volves relatively invasive and expensive techniques [2,3].
Therefore, along with continued and redoubled efforts to
understand the disease and develop new therapies,
numerous groups have set out to identify more sensitivethor. Tel.: 312-908-8152; Fax: 312-503-8152.
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e Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).(and perhaps less invasive) diagnostic approaches. Hinton
et al. [4] in 1986 identified histopathologic evidence of
axonal degeneration of the optic nerve and reduced thickness
of the retinal nerve fiber layer (RNFL) in patients with DAT,
making the eye a potential surrogate organ to detect the path-
ologic changes of the disease. Since then, multiple studies
have reported significant findings in the eyes of DAT pa-
tients, which was recently in a paper by by Javaid et al.
[5], which revealed at least 12 different visual or ocular po-
tential markers of the disease.
Over the past 25 years, optical coherence tomography
(OCT) has emerged as a powerful tool aiding in the diag-
nosis and management of various ocular diseases and forimer’s Association. This is an open access article under the CC BY-NC-ND
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diseases [6–11]. Advantages of OCT include that it is
noninvasive, readily available in most ophthalmology and
many neurology clinics, and can provide high-resolution
cross-sectional imaging of the RNFL and macula [12]. To
date, many researchers have reported RNFL thinning on
OCT in patients with DAT, and two recent meta-analyses
noted RNFL thinning affected all quadrants of the optic
nerve head [13,14].
Finding RNFL thinning in DAT is a milestone toward
validating the eye as a surrogate organ for disease detection
and monitoring. However, many researchers argue that early
detection should identify candidates for therapy before the
onset of cognitive impairment, as the damage is likely irre-
versible once symptoms arise [15]. With this insight there
is an interest in identifying early changes in subjects with
mild cognitive impairment (MCI). MCI is a clinical condi-
tion which can represent a transition to dementia of the Alz-
heimer type and consists of cognitive impairment on
standard tests but no impairment of activities of daily living.
Thus, MCI increases risk for DAT [2]. In particular, amnestic
MCI (aMCI), where episodic memory is impaired without
impairment of executive function, language, or other do-
mains, is viewed by some as prodromal DAT [1,16].
Several studies have used OCT to examine the RNFL in
subjects with a clinical diagnosis of MCI [17–26]. Ascaso
et al. [18] found all quadrants of the “peripapillary” RNFL
(except nasal) to be significantly thinner in aMCI subjects
compared with cognitively healthy controls. Similarly, Gao
et al. [20] found the temporal quadrant significantly thinner,
whereas Liu et al. [22] reported thinning in the superior
quadrant. In contrast, two other studies did not find signifi-
cant difference between aMCI and controls after adjusting
for confounders [19,25]. Coppola et al. [14] recently per-
formed a meta-analysis of two OCT studies in MCI, finding
all quadrants but superior significantly thinner. We believe
that the controversy in these studies is likely related to
high variability in the exclusion criteria, in cognitive testing,
and in rigor of adjustment for confounders.
Another potential explanation for the variable results
could relate to the unexplored variable of gliosis in the path-
ogenesis of DAT in the eye. Gliosis may precede the onset of
neuronal death and may therefore obfuscate the detection of
RNFL thinning. Gliosis is defined as hypertrophy and prolif-
eration of astrocytes and other glial cells and has been shown
to occur in the brain of DAT patients, correlating with the
duration of dementia [27,28]. Although it remains unclear
if gliosis is pathogenic, in animal models it has been found
to occur early on in the disease and is currently being
explored as a potential therapeutic target [29–31].
However, at this time, there have not been any
histopathologic or clinical studies exploring gliosis in the
eyes of aMCI subjects.
The present study was designed to address some of the
limitations of previous studies, by using a case-control study
design and strictly matching each aMCI subject to an age-,sex-, and race-matched control to minimize potential con-
founders [32,33]. We also ensured that controls underwent
the same rigorous cognitive testing as the aMCI
participants. We examined the “peripapillary” RNFL
thickness and retinal sublayers of the macula, particularly
the ganglion cell layer and inner plexiform layer (GC-
IPL), and explored their correlation with cognitive scores.
Finally, we performed a meta-analysis of the current world
literature.2. Materials and methods
2.1. Research study2.1.1. Study approval
The study was approved by the Institutional Review
Board of Northwestern University, and written informed
consent was obtained from all the participants.
2.1.2. Subjects
Twenty research participants with a clinical diagnosis of
aMCI were recruited from the Clinical Core of the North-
western Cognitive Neurology and Alzheimer’s Disease Cen-
ter (CNADC). The diagnosis of MCI was based on research
diagnostic criteria including the following: scores falling 2
or more standard deviations below the mean on neuropsycho-
logical tests within a battery used across the National Institute
on Aging ADC programs (i.e., the Uniform Data Set [UDS])
[34,35] and the absence of impairments of activities of daily
living as corroborated by a study partner [36]. Specifically,
we recruited aMCI participants, identified as only having
impairment in the memory domain. Participants had to be
capable of undergoing retinal imaging and those with ocular
pathology such as glaucoma, macular degeneration, diabetic
retinopathy, retinal detachment, ocular trauma, and extensive
cataracts were excluded. Further exclusion criteria included
neurologic disorders such as multiple sclerosis and Parkin-
son’s. Whenever possible, reported medical history was veri-
fied in the electronic medical record (EMR) to ensure that
participants’ reported history was accurate. Cognitively
normal control participants (N 5 20) were also recruited
from the CNADC, after undergoing the same neuropsycho-
logical battery as the MCI sample. These participants were
matched by age (within 3 years), race, and sex to the aMCI
sample. Control subjects had no abnormal test scores on the
UDS battery and all had normal activities of daily living as
reported by their study partners.
2.1.3. Ophthalmological assessments
Ophthalmological assessments included administration
of the National Eye Institute Visual Function Questionnaire
(VFQ-25). The VFQ-25 is a questionnaire that includes a 25-
item survey to evaluate self-reported vision-targeted health
status. Each score indicates a vision specific, health-related
quality of life measure. Participants underwent protocol
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each eye. Visual acuity was then measured using retro-
illuminated ETDRS charts at a testing distance of 3.2 m.
In addition, we tested contrast sensitivity in each eye sequen-
tially and both eyes together using the Pelli Robson chart at
1 m. Color vision was evaluated using the FM-15 L’anthony
desaturated panel and intra-ocular pressure using Tonopen
(Reichert Technologies, Buffalo, NY, USA).
2.1.4. Cognitive assessment
Extensive cognitive testing within a year of participation
in the present study had been performed by the CNADC. Par-
ticipants in the CNADC are examined at baseline and annu-
ally with the neuropsychological test battery of the UDS,
supplemented with the Rey Auditory Verbal Learning Test
(RAVLT), a measure of the ability to learn and retain a list
of 15 unrelated words [37]. The UDS includes tests of
learning and immediate and delayed episodic memory, lan-
guage, processing speed, attention, and executive function.
Participants also undergo a research neurological examina-
tion, provide a detailedmedical and family history, and desig-
nate a study partner from whom information is derived about
instrumental activities of daily living (iADL). In the current
study, we noted participants’ scores on RAVLT, immediate
and delayed recall of a short story [Logical Memory from
theWMS-R (LMI and LMII)], and part B of the Trail Making
Test (TMT-B), a test of executive attention. For all cognitive
exams except TMT-B, a higher score means better cognition.
TMTB is timed and, therefore, completing the test more
quickly, or a lower number, indicates better performance.
2.1.5. OCT imaging
Spectral domain OCT imaging was obtained with Spec-
tralis HRA 1 OCT (Heidelberg Engineering, Heidelberg,
Germany). “peripapillary” RNFL thickness and macular
volume scans were performed. Dilation of each eye was per-
formed before imaging.
2.1.6. Macular sublayer segmentation
For each macular volumetric scan, the macular sublayer
thicknesses were extracted semiautomatically, as previously
described using validated segmentation software, Duke Op-
tical Coherence Tomography Retinal Analysis Program
(DOCTRAP) [38]. Briefly, the software defined six retinal
sublayers including GCL/IPL. Automated grading was fol-
lowed by a two-grader quality-control procedure to further
examine segmentation boundaries and perform any manual
corrections, as previously described [39]. Sublayer thick-
nesses were automatically measured in each scan, and
average macular sublayer thicknesses were calculated for
each volumetric scan. OCT graders were masked to partici-
pant group assignment.
2.1.7. Statistical analysis
Statistical analysis was performed using the Statistical
Analysis System, version 9.4 (SAS Institute, Raleigh, NC,USA). aMCI and control groups were compared regarding
OCT thickness measures using repeated-measures analysis
of variance accounting for layer and eye within person.
Analysis of covariance (ANCOVA) was used to relate the
thickness measures to the cognitive scores. Regression coef-
ficients were calculated to identify the change in thickness
measure per unit change in cognitive scores. Effect size
was also calculated to determine if the small sample size
was the main variable affecting results. ANCOVAwas then
used to adjust for hypertension and diabetes.2.2. Meta-analysis2.2.1. Key question
We conducted a meta-analysis of the world literature to
determine if RNFL thinning is a consistent marker in sub-
jects with MCI.
2.2.2. Search strategy
A computerized search of PubMed, Medline, Scopus,
Google Scholar, Web of Science, and Cochrane Library
was performed. Reference lists from reviews and studies
were also manually searched. Keywords included mild
cognitive impairment, MCI, optical coherence tomography,
OCT, retinal nerve fiber layer thickness, “peripapillary”
RNFL, and retinal thickness.
2.2.3. Study assessment and data extraction
Full-text articles were included if they met the following
criteria: (1) the study was designed to compare RNFL thick-
ness between MCI and control participants using OCT and
included analysis of all quadrants of the RNFL (superior,
temporal, nasal, and inferior quadrants); (2) the study
actively excluded participants who had confounding ocular
and neurologic diseases; (3) the study adjusted for age differ-
ences between MCI and controls; (4) the study performed
rigorous cognitive examination of bothMCI and control par-
ticipants; and (5) the study had an MCI and control group
with all OCT data available in the article. We were unable
to limit our meta-analysis to aMCI because most studies
did not distinguish this subgroup from other forms of MCI.
One investigator (BK) conducted the literature search and
two investigators (BK and JS), masked to names of authors
and journals, independently reviewed each of the identified
manuscripts to rate their quality as good, fair, or poor based
on the criteria specified previously. Discrepancies were
resolved by adjudication of a third reviewer (AAF).
2.2.4. Statistical analysis
The meta-analysis was conducted following the Co-
chrane Collaboration guidelines and was analyzed using
Comprehensive Meta-Analysis (Biostat, Englewood, NJ,
USA) [40]. “peripapillary” RNFL thickness was extracted
including the mean 6 standard deviation from each article.
The I2 statistic was calculated to determine heterogeneity
Table 1






(n 5 17) P value
Variables
Female 13 13 —
Age
60–70 5 5 —
71–80 7 7 —
81–90 5 5 —
Average 74 74 —
Race
African American 5 5 —
Caucasian 12 12 —
Hypertension* 7/17 8/17 —
Diabetes* 6/17 3/17 —
Average RAVLT (total 5 15) 5.0 6 3.91 11.1 6 2.87 ,.001
Average LMI (total 5 25) 8.7 6 3.12 16.3 6 3.35 ,.001
Average LMII (total 5 25) 7.3 6 4.55 16.35 6 4.50 ,.001
Average TMT-By 106.6 6 224.67 80.3 6 34.95 .07
Average MMSE (total 5 30) 27 6 3.72 29 6 0.70 .03
Abbreviations: aMCI, amnestic mild cognitive impairment; RAVLT, Rey
Auditory Verbal Learning Test; LMI, logical memory test I or immediate
recall; LMII, logical memory test II or delayed recall; TMT-B, Trail Making
Test, part B; MMSE, Mini-Mental State Examination.
*Subjects with retinopathy related to hypertension or diabetes were
excluded.
yTMT-B scores generally fell within normal limits for the age group
studied.
Table 2
OCT: RNFL and macular sublayer thickness results





Right eye 91.8 6 11 91.8 6 11 .99
Left eye 89.3 6 15 90.2 6 12 .86
Superior
Right eye 104.8 6 15 106.9 6 16 .66
Left eye 105.2 6 23 105.4 6 20 .99
Inferior
Right eye 121.2 6 19 120.4 6 22 .91
Left eye 118 6 23 118.8 6 18 .90
Nasal
Right eye 76 6 21 72.6 6 17 .61
Left eye 71.4 6 18 68.9 6 21 .72
Temporal
Right eye 65.6 6 17 67.4 6 13 .72
Left eye 62.5 6 15 67.7 6 17 .32
Macula volume (mm3)
Right eye 8.14 6 0.58 8.29 6 0.56 .51
Left eye 8.21 6 0.51 8.28 6 0.51 .51
Macula GC-IPL (mm)
Right eye 385 6 39 390 6 46 .74
Left eye 287 6 38 388 6 45 .93
Abbreviations: OCT, optical coherence tomography; RNFL, retinal nerve
fiber layer; aMCI, amnestic mild cognitive impairment; GC-IPL, ganglion
cell layer and inner plexiform layer.
*n 5 16 for right eye and 17 for left eye.
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ing a random-effects model based on the I2 value, also per
the Cochrane Collaboration guidelines. Effect size is re-
ported as Hedges g given the small sample sizes [42].
Finally, Egger test for publication bias was calculated [43].
A P value ,.05 was considered statistically significant.Table 3
Regression coefficients (P values) correlating “peripapillary” RNFL thick-




RNFL quadrant P values
Temporal Nasal Superior Inferior
LMI 0.40 (.55) 0.24 (.67) 20.95 (.19) 21.11 (.14)
LMII 20.14 (.78) 0.31 (.45) 21.18 (.022)* 21.35 (.012)*
RAVLT 20.28 (.64) 0.42 (.31) 20.65 (.39) 21.79 (.026)*
Abbreviations: RNFL, retinal nerve fiber layer; LMI, logical memory test
I or immediate recall; LMII, logical memory test II or delayed recall;
RAVLT, Rey Auditory Verbal Learning Test.
*Statistically significant P value ,.05.3. Results
3.1. Experimental study
Of the 20 aMCI participants recruited, 3 were excluded: 2
because of an established diagnosis of glaucoma in the EMR
and 1 because of macular degeneration discovered on OCT
imaging. One eye of a study participant was excluded
because of trauma in childhood. The remaining eligible par-
ticipants were 17 aMCI subjects (33 eyes). Characteristics of
the case-control groups are listed in Table 1. Although the
mean TMT-B score for the aMCI group was worse than
for controls, the overall value was within normal range for
age and the difference between groups was not statistically
significant. Thus, TMT-B was excluded from further anal-
ysis.
RNFL thickness, macular sublayer thickness, and total
macular thickness/volume comparisons between aMCI and
controls are shown in Table 2. We found no statistically sig-
nificant difference between aMCI and control groups in
terms of RNFL thickness for all quadrants. Effect size wascalculated, and the largest effect for RNFL thickness was
0.41, indicating that the small sample size alone does not ac-
count for the difference and that the groups truly are very
similar. There was no significant difference between the
two groups with respect to contrast sensitivity, visual acuity,
color vision, VFQ-25, and IOP. ANCOVA adjustment for
diabetes and hypertension did not alter the results.
Table 3 shows the regression coefficients (P values) for
the relationships between cognitive scores and RNFL thick-
ness in our aMCI participants. There was a statistically sig-
nificant negative correlation between LMII and the RNFL
superior and inferior quadrants and a significant negative
correlation between RAVLT and the RNFL inferior
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tive quadrants correlated with better cognitive scores.3.2. Meta-analysis3.2.1. Studies included
The initial search yielded 71 hits, from which a final list
of 12 relevant articles was identified for further review.
Three articles were excluded because of lack of raw OCT
data and two because of poor exclusion criteria. Finally,
one article used the term “mild cognitive criteria” to refer
to newly diagnosed DAT. The remaining six studies were
selected for the meta-analysis based on the quality criteria
as determined by the three reviewers.
Table 4 summarizes detailed demographic and OCT data
for the final selected articles, which includes 161 MCI par-
ticipants and 300 controls [18-22,25]. In the last row, we
have inserted data from the present study for comparison.
Included studies were based in Spain, China, Israel, and
Singapore. The quality of diagnosis was deemed fair
because of lack of clear cognitive testing methodology or
lack of adjustment for confounders.
We first examined heterogeneity of RNFL thickness mea-
surements in MCI and control subjects. The I2 value was
88.2%, which indicates high heterogeneity, and thus, a
random-effects analysis was performed. Based on the small
sample size and different imaging modalities used to mea-
sure the RNFL thickness, a Hedges g value was calculated.
These values are shown in Table 5. The forest plots for
this data are shown in Fig. 1. Finally, we conducted a publi-
cation bias analysis, and the Egger regression intercept was
22.67 (95% confidence interval from27.35 to 2.00) with a
P value of .25, indicating an unbiased study.4. Discussion
The major finding from this case-control study was an ab-
sent statistically significant difference in RNFL and macular
sublayers comparing aMCI and matched cognitively healthy
control participants. This finding was consistent with some
previous studies but differed from others. Our findings sug-
gest that in a well-characterized sample, where aMCI had
MCI (average Mini-Mental State Examination
[MMSE] 5 27.3) and were carefully matched to controls,
retinal thickness measured with OCT does not correlate
with cognitive status, a finding supported by an RNFL effect
size of 0.41 suggesting very similar populations, rather than
low power of our study.
A secondary finding was an inverse relationship be-
tween “peripapillary” RNFL and test scores of two cogni-
tive tests: the superior and inferior RNFL quadrants and
delayed story recall (LMII) and thickness of the inferior
RNFL quadrant and word-list learning test (RAVLT). An
inverse relationship implies that with lower cognitive
test scores, the RNFL is thicker. Although this appearsparadoxical at first, a potential explanation could relate
to pathologic gliosis preceding loss of neurons and ulti-
mate decreased thickness, a pathologic finding that has
been shown in other degenerative eye diseases [44]. In
particular, the superior RNFL quadrant may be an ideal
location to distinguish patients at risk for DAT because
it would be a distinct location from the inferior quadrant,
which is usually involved early on glaucoma patients,
another age-related optic neuropathy [45]. Gliosis may
also explain the lack of statistically significant difference
in RNFL thickness between our aMCI participants and
matched controls. Given that multiple studies have shown
thinning in the retina of DAT patients, it is possible that
gliosis occurs first in the disease process, leading to lack
of difference or an initial paradoxical increase in RNFL
thickness on OCT. Then, with disease progression, axonal
degeneration and RNFL thinning proceed in DAT, at
which point RNFL thinning can be discerned on OCT
with statistical significance.
Further support for the gliosis hypothesis stems from his-
topathologic studies that show gliosis is an early marker of
DAT pathology in the brain [28,29]. In the eyes, gliosis
has also been demonstrated in a rat model of glaucoma, an
ocular condition also known to ultimately cause RNFL
thinning [44,45]. It is now hypothesized that in glaucoma,
RNFL gliosis occurs first and is then followed by thinning
that can be identified on OCT in later stages [46]. Unfortu-
nately, OCT imaging of the RNFL does not reveal a unique
signature for gliosis. With the availability of new modalities
of retinal imaging, such as the adaptive optics scanning laser
ophthalmoscope (AO-SLO), it is now possible to visualize
the RNFL in greater detail because of the enhanced lateral
resolution of these technologies [47,48]. The inverse
correlation between RNFL and cognitive function in aMCI
subjects would suggest that gliosis could also be occurring
in these eyes. We believe this finding is important, as it
may actually explain the variability in the previous OCT
reports and may partly explain the previous reports that
failed to identify a difference between controls and aMCI.
If the earliest change in the retina of aMCI subjects were
gliosis of the inner retina and hence “thickening of the
RNFL” based on our findings, this would necessitate a
significantly changed approach for early detection of AD
in the eye. Our work, and validation by other studies in
different populations, could lead to a paradigm shift in the
field.
This case-control study carries several major strengths
that distinguish it from the previous reports. We included a
strictly defined population of aMCI subjects, who are theo-
retically at the greatest risk of advancing on to DAT, subjects
were carefully matched to healthy controls, and the entire
study population underwent visual function tests by the
same researcher. Furthermore, a board-certified ophthal-
mologist, retina specialist, carefully evaluated all the OCT
images to ensure exclusion of subjects with confounding
age-related ocular pathology. In addition, the cognitive tests
Table 4















Ascaso et al. 2014 Spain 21 72.1 6 8.7 19.3 41 72.9 6 7.9 Fair 87.3 6 7.22*
Gao et al. 2014 China 26 73.4 6 1.5 25.8 21 72.1 6 1.0 Good 92.38 6 1.94
Kesler et al. 2011 Israel 24 71.0 6 10.0 28.1 24 70.9 6 9.2 Fair 85.8 6 10.0*
Shen et al. 2014 China 23 74.4 6 3.2 22.2 52 74.1 6 2.6 Good 82.6 6 10.5
Liu et al. 2015 China 26 70.2 6 6.5 — 39 69.7 6 7.8 Fair 95.4 6 17.11
Cheung et al. 2015 Singapore 41 70.4 6 10.2 — 123 65.7 6 3.8 Fair 87.3 6 7.22
Knoll et al. Present
study
USA 17 74.5 6 8.9 27.3 17 74.8 6 8.3 Good 90.2 6 12.2
Abbreviations: MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; RNFL, retinal nerve fiber layer; SD, standard deviation.
*Study found significant difference between MCI and controls in this quadrant.
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diagnosis and were performed by trained professionals at
the CNADC. Finally, we verified reported past medical his-
tory against the EMR, whenever possible. This additional
verification allowed us to identify and exclude two partici-
pants with underlying glaucoma who would otherwise
have been missed because they self-reported no history of
ocular disease.
There are several limitations of our study. Because of the
interactive nature of these tests, the researcher who per-
formed the cognitive and visual function tests could not be
masked to participant group. The small sample size could
be a limitation; however, given the small effect size of
RNFL, we believe the lack of significance likely represent
true absence of difference between the two groups. Overall,
the small sample size remains an important limitation in our
study and others in this line of research, given the need to
exclude glaucoma and other neurologic and age-related
ocular diseases, to avoid confounding. Finally, in this study,
we did not use brain imaging to rule out vascular pathology.
Nevertheless, we do not believe this is a limitation of our
study, given that current cognitive testing, such as that per-
formed by Northwestern CNADC, is designed and validated
to distinguish vascular type dementia from dementia of Alz-
heimer’s type.
With these study size limitations in mind, we performed
the meta-analysis, which showed that MCI subjects (notTable 5






g value P value Q value P value I2
Total 21.27 .003 90.94 ,.001 93.40
Superior 21.09 .004 77.33 ,.001 92.25
Inferior 20.80 .001 30.89 ,.001 80.58
Nasal 20.45 ,.001 8.33 .215 27.94
Temporal 20.70 .014 45.38 ,.001 86.78
Abbreviation: RNFL, retinal nerve fiber layer.limited to aMCI) had statistically significant thinning of
the RNFL that affected all quadrants of the optic nerve,
compared with cognitively intact control population. Over-
all, by combining these relatively small studies including
our own, we identified evidence that ocular involvement re-
vealed on OCT is likely present at this early stage. Strengths
of the meta-analysis include rigorous exclusion and inclu-
sion criteria and quality analysis of each article. Our findings
are in line with a recent meta-analysis in subjects with DAT,
which showed reduced RNFL thickness compared with
cognitively healthy controls [14].
In examining the current world literature, we identified
high variability among studies with regard to methodology
as a significant limitation. Significantly, the exclusion criteria
for confounding diseases varied from study to study. For
example, many studies did not state whether an ophthalmolo-
gist was involved to ensure exclusion of confounding ocular
pathology, and it was not always stated how subjects were
screened for confounding diseases. Furthermore, many
studies compared the mean ages of their MCI and control
groups but did not adjust for age or race in the final analysis.
Additionally, many studies relied only on the MMSE to char-
acterize cognitively normal control subjects, which may not
be ideal as shown by a recent review that concluded that
MMSE alone is not sufficient to distinguish participants
withMCI from controls [49].Wewere also unable to compare
the OCT data with cognitive scores in other studies because
there was great deal of inconsistency in reporting cognitive
data. Finally, although our case-control study focused on
aMCI, most previous studies did not specify the specific
axis of cognitive impairment in their MCI population, likely
including a widely heterogeneous MCI population.
In summary, our case-control study revealed that OCT
findings may be subtle in a well-defined subpopulation of
aMCI and that “peripapillary”RNFLmay be inversely related
to cognitive tests, suggesting a potential role for gliosis in this
population. Themeta-analysis suggested that theRNFL is sta-
tistically significantly thinner in subjectswithMCI, compared
with cognitively healthy controls. Unfortunately, most previ-
ous studies have used inconsistent methodology and had
Total RNFL Superior Inferior Nasal Temporal
Control MCI Control MCI Control MCI Control MCI Control
102.7 6 6.89* 104.0 6 15.74* 128.2 6 14.4* 111.1 6 19.0* 132.7 6 13.25* 65.9 6 17.6 75.9 6 13.3 68.5 6 16.5* 74.9 6 13.5*
98.60 6 1.67 112.12 6 3.31 122.25 6 2.95 123.87 6 3.36 127.59 6 2.72 68.54 6 1.52 69.71 6 1.55 66.56 6 2.44* 74.60 6 2.11*
94.3 6 11.3* 101.3 6 15.2 110.0 6 16.7 111.9 6 16.1* 127.0 6 15.5* 65.9 6 15.1 76.4 6 21.8 64.2 6 13.9 67.8 6 15.1
85.6 6 10.2 101.8 6 16.8 104.7 6 15.4 104.5 6 17.6 109.3 6 21.3 61.5 6 8.1 64.8 6 8.4 62.7 6 12.2 65.5 6 10.1
100.12 6 15.0 115.14 6 13.5* 119.1 6 15.3* 120.23 6 18.0 125.7 6 11.2 74.8 6 12.36 79.9 6 12.9 63.8 6 13.2 67.34 6 15.3
102.7 6 6.89 104.0 6 15.74 128.2 6 14.4 111.1 6 19.0 132.7 6 13.25 65.9 6 17.6 75.9 6 13.3 68.5 6 16.5 74.9 6 13.5
91.0 6 10.5 106.8 6 18.2 106.2 6 18.8 120.0 6 18.6 119.2 6 17.4 75.3 6 19.5 68.2 6 21.6 65.1 6 15.1 67.8 6 16.2
B. Knoll et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 4 (2016) 85-93 91variable results, which highlights the need to initiate large
population prospective standardizedOCT studies. Ultimately,
the goal is to identify an ocular imaging modality that is
capable of identifying aMCI patients who are at the highest
risk of developing DAT. We foresee that a multidisciplinary,Fig. 1. Forest plots for retinal nerve fiber layer thickness (by quadrant) comparing
model.longitudinal approach with stringent cognitive testing,
including high-resolution technologies such as AO-SLO,
will be required to identify and perhaps predict those individ-
uals who are highest risk for DAT, so that they can be targeted
for preventive therapies as these become available.participants with mild cognitive impairment with controls using Hedges g
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1. Systematic review: Ocular involvement in mild
cognitive impairment (MCI) remains a subject of
controversy. Previous literature suffers from lack of
standardized protocols to define MCI, exclude, and/
or adjust for confounders. To address these defi-
ciencies, we performed a rigorous case-control
study focusing on amnestic MCI (aMCI) partici-
pants.
2. Interpretation: Our study found no statistically sig-
nificant difference in optical coherence tomography
(OCT) between aMCI subjects and controls, but un-
covered that OCT thickness was significantly
(inversely) related to cognitive scores. The meta-
analysis showed statistically significant thinning in
MCI subjects compared with controls.
3. Future direction: Overall, ocular involvement inMCI
may be more complex than previously thought. With
this in mind, we believe that longitudinal OCT
studies are needed to explore whether OCT can pre-
dict aMCI subjects at risk for Alzheimer’s disease.
Based on the inverse relationship found, we suggest
future studies incorporate new retinal imaging mo-
dalities that are capable of examining the complex
retinal pathology.References
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